Results 101 to 110 of about 91,755 (270)
Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem +20 more
wiley +1 more source
Purpose: The aim of this study was to evaluate the cost-effectiveness of nivolumab versus ipilimumab for the treatment of previously untreated patients with BRAF-advanced melanoma (BRAF-AM) from an Australian health system perspective.
Liew, Danny +5 more
core +1 more source
Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers
ABSTRACT Immune checkpoint inhibitors such as anti–PD‐1 antibodies are essential in cancer therapy. Emerging data suggest that lower doses may be effective and more economical, though further evidence is needed. We conducted a retrospective study at Centre Léon Bérard to assess the efficacy and safety of low‐dose nivolumab (20 mg every 3 weeks) in ...
Thibault Gauduchon +16 more
wiley +1 more source
ABSTRACT Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real‐world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry.
Julien Bollard +23 more
wiley +1 more source
ABSTRACT Neoadjuvant therapy has recently become an integral component of multimodal treatment for resectable lung cancer. However, real‐world data on perioperative morbidity and treatment adherence remain limited. This study aimed to assess the feasibility and safety of different neoadjuvant treatment approaches applied within daily clinical routine ...
Raffaella Griffo +14 more
wiley +1 more source
Introduction Pazopanib, a tyrosine kinase inhibitor, and nivolumab, an immune checkpoint inhibitor, are both considered to cause hepatotoxicity with different pathophysiology.
Maki Todo +8 more
doaj +1 more source
ABSTRACT Clinical data on combined Immunotherapy (IO) and palliative radiotherapy (RT) in HNSCC is scarce. HNSCC Palliative RT differs from curative intent RT as it does not involve elective nodal irradiation; therefore, an immune response may be more likely.
Chris Hurt +21 more
wiley +1 more source
BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated.
Wei Chen +8 more
doaj +1 more source
Virion production and cell viability in response to nivolumab.
Median virion production across all donors in response to nivolumab (Fig 2A). Median-fold difference in cell viability across all donors in response to nivolumab or anti-CD3/CD28 stimulation compared to isotype control (Fig 2B).
Joshua C. Cyktor (385345) +5 more
core +1 more source
Integrated multi‐omics reveals that CD36‐mediated lipid overload in PBMCs drives T cell exhaustion via sub‐lethal ferroptotic stress and AKT suppression. This systemic metabolic signature serves as a robust predictor of immunotherapy response in HCC, suggesting that modulating lipid metabolism can rescue immune fitness.
Ying Zhu +6 more
wiley +1 more source

